Modeling and Simulation - PK/PD Archives | 第 3 页，共 46 页 | Certara

Publication

Model-Based Meta-Analysis of Objective Response Rate and Survival Endpoints to Compare PD-1 and PD-L1 Treatment Outcomes in Non-Small Cell Lung Cancer

This study used model-based meta-analysis (MBMA) to assess how well objective response rate (ORR) predicts…

Danielle Pillsbury2026 年 3 月 4 日

Blog

ADC 首次人体（FIH）剂量选择：成功设计 FIH 研究的关键

Optimize ADC First-in-Human Dose Selection with model-informed strategies and exposure–response insights to design safer, more…

Certara2026 年 3 月 3 日

Live Events

Phoenix Roadshow 2026 – 英国剑桥

Certara2026 年 3 月 2 日

Live Events

Phoenix Roadshow 2026 – 美国罗利-达勒姆

Certara2026 年 3 月 2 日

Blog

拥抱模型引导的药物发现：通往更佳临床疗效之路

We cover the evidence of biosimulation improving clinical success rates, making the case for model-informed…

Certara2026 年 2 月 27 日

Live Events

Phoenix Roadshow 2026 – Philadelphia

Certara2026 年 2 月 27 日

On-Demand Webinar

Formulate Faster: A Purpose-Built Toolkit for Bioequivalence (Phoenix IVIVC Toolkit)

This webinar introduces the Phoenix IVIVC Toolkit, showing how to perform BE analysis and build…

Certara2026 年 2 月 27 日

Webinar

Maximizing the Impact of Antibody–Drug Conjugates (ADCs): Model-Informed Labeling, Expansion, and Market Access

Danielle Pillsbury2026 年 2 月 23 日

Webinar

Optimal Dosing, Optimal Outcomes: Model-Based Approaches for Antibody–Drug Conjugates (ADCs)

Certara2026 年 2 月 23 日

Webinar

Strong starts, confident finishes: Optimizing first-in-human strategies for antibody–drug conjugates (ADCs)

Certara2026 年 2 月 23 日

© 2026 Certara. 保留所有权力。 | 法律 | 隐私政策

沪ICP备2022021526号

Powered by Translations.com GlobalLink Web Software